Chapter 10
Curriculum Vitae.
Publications.

CURRICULUM VITAE

The author of this thesis was born at the 21st of March 1983 in Woerden, The Netherlands. During her gymnasium education at the Christelijk Lyceum Veenendaal, she became fascinated by genetics and disease pathogenesis, especially the development of cancer. After graduation in 2001, she pursued a career in molecular biology and studied biology and medical laboratory research at the Hogeschool van Utrecht. During this bachelor program, she did a 12-months internship at the department of Experimental Therapy of the Netherlands Cancer Institute, in the group of Prof. Dr. L.J. van 't Veer. She graduated half a year early and spent these months as a researcher at the same department. In August 2005, she started the master program in Oncology at the VU University Medical Center in Amsterdam. She did her internship at the department of Pathology of the VU University Medical Center, in the group of Prof. Dr. G.A. Meijer. In addition, she spent six months in London (UK) at the department of Gene Function of the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, in the group of Prof. Dr. A. Ashworth. Upon graduation she received the Top master Oncology degree.
In October 2007, she started her PhD training at the department of Otolaryngology-Head and Neck Surgery of the VU University Medical Center under supervision of Prof. Dr. R.H. Brakenhoff. During this project she focused on the identification of novel drug targets for the personalized treatment of head and neck cancer. The results of this PhD research project are presented in this thesis. These data were also used to start a new research project in 2012, which particularly focused on the development of novel cancer treatments for Fanconi anemia patients suffering from head and neck cancer. In 2013, the data from the microRNA studies presented in this thesis were the basis for an FP7 EU research application that was granted, which focuses on the therapeutic application of microRNAs in the treatment of head and neck cancer. The author of this thesis is involved in both projects as a postdoctoral researcher.

PUBLICATIONS

Rietbergen MM, **Martens-de Kemp SR**, Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, Leemans CR, Braakhuis BJM, Brakenhoff RH.
Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with HPV-positive oropharyngeal cancer.
European Journal of Cancer, in press. doi: 10.1016/j.ejca.2013.11.010.

Lindenbergh-van der Plas M, **Martens-de Kemp SR**, de Maaker M, van Wieringen WN, Ylstra B, Agami R, Cerisoli F, Leemans CR, Braakhuis BJ, Brakenhoff RH.
Identification of lethal microRNAs specific for head and neck cancer.
Clin Cancer Res. 2013;19(20):5647-57. doi: 10.1158/1078-0432.CCR-12-2295.

Nagel R, **Martens-de Kemp SR**, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH.
Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.
Oral Oncol. 2013;49(6):560-6. doi: 10.1016/j.oraloncology.2013.03.446.

Martens-de Kemp SR, Brink A, Stigter-van Walsum M, Damen JM, Rustenburg F, Wu T, van Wieringen WN, Schuurhuis GJ, Braakhuis BJ, Slijper M, Brakenhoff RH.
CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties.
Stem Cell Res. 2013;10(3):477-88. doi: 10.1016/j.scr.2013.02.004.

Martens-de Kemp SR, Dalm SU, Wijnolts FM, Brink A, Honeywell RJ, Peters GJ, Braakhuis BJ, Brakenhoff RH.
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
PLoS One. 2013;8(4):e61555. doi: 10.1371/journal.pone.0061555.

Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Clin Cancer Res. 2013;19(8):1994-2003. doi: 10.1158/1078-0432.CCR-12-2539.

Iorns E, **Martens-de Kemp SR**, Lord CJ, Ashworth A.
CRK7 modifies the MAPK pathway and influences the response to endocrine therapy.
Carcinogenesis. 2009;30(10):1696-701. doi: 10.1093/carcin/bgp187.

Knoops L, Haas R, **de Kemp SR**, Majoor D, Broeks A, Eldering E, de Boer JP, Verheij M, van Ostrom C, de Vries A, van't Veer L, de Jong D.
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma.
Blood. 2007;110(4):1116-22.

Schmidt MK, Tollenaar RA, **de Kemp SR**, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ.
*Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.*
J Clin Oncol. 2007;25(1):64-9.

Chapter 11
Dankwoord.